Bio-Path (NASDAQ:BPTH) Announces Quarterly Earnings Results

Bio-Path (NASDAQ:BPTHGet Free Report) released its earnings results on Friday. The company reported ($5.40) EPS for the quarter, hitting the consensus estimate of ($5.40), Yahoo Finance reports. During the same quarter in the previous year, the firm earned ($10.60) earnings per share.

Bio-Path Stock Down 6.4 %

Shares of NASDAQ BPTH traded down $0.40 during trading on Friday, hitting $5.83. 27,872 shares of the company traded hands, compared to its average volume of 18,298. Bio-Path has a 1 year low of $4.60 and a 1 year high of $44.80. The company has a 50-day moving average price of $8.49 and a 200-day moving average price of $9.26.

Institutional Trading of Bio-Path

Several institutional investors have recently made changes to their positions in BPTH. Walleye Capital LLC purchased a new stake in shares of Bio-Path during the 3rd quarter valued at $77,000. Vanguard Group Inc. lifted its holdings in shares of Bio-Path by 77.5% during the 4th quarter. Vanguard Group Inc. now owns 270,029 shares of the company’s stock valued at $125,000 after acquiring an additional 117,914 shares in the last quarter. Renaissance Technologies LLC acquired a new position in shares of Bio-Path during the 2nd quarter valued at $70,000. Citadel Advisors LLC acquired a new position in shares of Bio-Path during the 3rd quarter valued at $35,000. Finally, Virtu Financial LLC acquired a new position in shares of Bio-Path during the 1st quarter valued at $38,000. 5.74% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, StockNews.com initiated coverage on shares of Bio-Path in a research note on Thursday. They issued a “sell” rating for the company.

Read Our Latest Stock Report on BPTH

Bio-Path Company Profile

(Get Free Report)

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.

Featured Articles

Earnings History for Bio-Path (NASDAQ:BPTH)

Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.